RN9101 Treatment for Hard-to-Treat Multiple Myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Diagnosed with multiple myeloma that has relapsed (come back) or is refractory (resistant to prior treatments) after at least 2 previous treatment lines
- Confirmed BCMA protein expression on myeloma cells (detected via lab testing)
- Measurable disease at screening (detectable myeloma markers in blood, urine, or imaging)
- Good overall health with ECOG performance status 0–2 (able to carry out daily activities with minimal assistance) and life expectancy of at least 3 months
- Adequate organ function: bone marrow, kidney, liver, heart, and lung function must meet specific thresholds
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This early-stage trial tests a new drug called QI-019B in patients whose multiple myeloma (a blood cancer) has stopped responding to standard treatments. The study checks if QI-019B is safe and whether it helps slow or stop the cancer's growth.
This trial tests a new drug called QI-019A for people whose multiple myeloma has returned or stopped responding to at least two prior treatments. The goal is to see if it is safe and if it can help control the disease.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This trial tests a new cell therapy called RN1201 for people with a high-risk type of multiple myeloma. It’s designed to target two specific markers on myeloma cells (BCMA and CD19) and may be given after initial treatment to help keep the cancer from coming back.
Hear when a new Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.